The Latest Breaking News from Bluebird bio

 

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

According to Benzinga Pro data, during Q1, bluebird bio (NASDAQ:BLUE) posted sales of $1.95 million. Earnings were up 21.22%, but bluebird bio still reported an overall loss of $122.15 million.

Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of 

The